메뉴 건너뛰기




Volumn 39, Issue 1, 2012, Pages 9-12

Effect of fluvoxamine on the pharmokinetics of zolpidem: A two-treatment period study in healthy volunteers

Author keywords

Drug interaction; Fluvoxamine; Pharmacokinetics; Zolpidem

Indexed keywords

FLUVOXAMINE; ZOLPIDEM;

EID: 84855170546     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05625.x     Document Type: Article
Times cited : (9)

References (22)
  • 1
    • 0029074925 scopus 로고
    • Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications
    • Salvà P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin. Pharmacokinet. 1995; 29: 142-53.
    • (1995) Clin. Pharmacokinet. , vol.29 , pp. 142-153
    • Salvà, P.1    Costa, J.2
  • 2
    • 0032986686 scopus 로고    scopus 로고
    • Zolpidem metabolism in vitro: Responsible cytochromes, chemical inhibitors, and in vivo correlations
    • Von Moltke LL, Greenblatt DJ, Granda BW et al. Zolpidem metabolism in vitro: Responsible cytochromes, chemical inhibitors, and in vivo correlations. Br. J. Clin. Pharmacol. 1999; 48: 89-97.
    • (1999) Br. J. Clin. Pharmacol. , vol.48 , pp. 89-97
    • Von Moltke, L.L.1    Greenblatt, D.J.2    Granda, B.W.3
  • 3
    • 12944331138 scopus 로고    scopus 로고
    • Zolpidem. A review of its use in the management of Insomnia
    • Harrison TS, Keating GM. Zolpidem. A review of its use in the management of Insomnia. CNS Drugs 2005; 19: 65-89.
    • (2005) CNS Drugs , vol.19 , pp. 65-89
    • Harrison, T.S.1    Keating, G.M.2
  • 4
    • 67349106390 scopus 로고    scopus 로고
    • Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem
    • Farkas D, Volak LP, Harmatz JS, von Moltke LL, Court MH, Greenblatt DJ. Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. Clin. Pharmacol. Ther. 2009; 85: 644-50.
    • (2009) Clin. Pharmacol. Ther. , vol.85 , pp. 644-650
    • Farkas, D.1    Volak, L.P.2    Harmatz, J.S.3    von Moltke, L.L.4    Court, M.H.5    Greenblatt, D.J.6
  • 5
    • 84855162939 scopus 로고    scopus 로고
    • Sanofi-Aventis US LLC
    • Prescribing information. (Online); Available from: (accessed 18 August)
    • Sanofi-Aventis US LLC. Ambiem (zolpidem tartrat) tablets CIV: Prescribing information. (Online); Available from: (accessed 18 August 2011).
    • (2011) Ambiem (zolpidem tartrat) tablets CIV:
  • 9
    • 0031025875 scopus 로고    scopus 로고
    • Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism
    • Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin. Pharmacokinet. 1997; 32(Suppl. 1): 1-21.
    • (1997) Clin. Pharmacokinet. , vol.32 , Issue.SUPPL. 1 , pp. 1-21
    • Preskorn, S.H.1
  • 10
    • 48549093980 scopus 로고    scopus 로고
    • Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update
    • Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update. Clin. Ther. 2008; 30: 1206-27.
    • (2008) Clin. Ther. , vol.30 , pp. 1206-1227
    • Spina, E.1    Santoro, V.2    D'Arrigo, C.3
  • 11
    • 0029160813 scopus 로고
    • Overview of the pharmacokinetics of fluvoxamine
    • van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin. Pharmacokinet. 1995; 29(Suppl. 1): 1-9.
    • (1995) Clin. Pharmacokinet. , vol.29 , Issue.SUPPL. 1 , pp. 1-9
    • van Harten, J.1
  • 12
    • 0031979755 scopus 로고    scopus 로고
    • Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications
    • Caccia S. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin. Pharmacokinet. 1998; 34: 281-302.
    • (1998) Clin. Pharmacokinet. , vol.34 , pp. 281-302
    • Caccia, S.1
  • 13
    • 0023615056 scopus 로고
    • A comparison of the 2 one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability
    • Schuirmann DJ. A comparison of the 2 one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokinet. Biopharm. 1987; 15: 657-80.
    • (1987) J. Pharmacokinet. Biopharm. , vol.15 , pp. 657-680
    • Schuirmann, D.J.1
  • 14
    • 84855163759 scopus 로고    scopus 로고
    • U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research
    • Bioavailability and bioequivalence studies for orally administered drug products-general considerations. July 2002. (online) Available from: (accessed 18 August)
    • U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products-general considerations. July 2002. (online) Available from: (accessed 18 August 2011).
    • (2011) Guidance for industry
  • 15
    • 84855163762 scopus 로고    scopus 로고
    • The European Agency for the Evaluation of Medicinal Products, Committee for medicinal products for human use
    • London, January 2010. (online) Available from: (accessed 18 August).
    • The European Agency for the Evaluation of Medicinal Products, Committee for medicinal products for human use. Guideline on the investigation of bioequivalence. London, January 2010. (online) Available from: (accessed 18 August 2011).
    • (2011) Guideline on the investigation of bioequivalence
  • 16
    • 84855163759 scopus 로고    scopus 로고
    • U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research
    • In vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling. November 1999. (online). Available from: (accessed 18 August)
    • U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. In vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling. November 1999. (online). Available from: (accessed 18 August 2011).
    • (2011) Guidance for industry
  • 17
    • 84855162938 scopus 로고    scopus 로고
    • U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. Draft guidance. In vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling. September 2006. (online) Available from: (accessed 18 August 2011)
    • U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. Draft guidance. In vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling. September 2006. (online) Available from: (accessed 18 August 2011).
  • 19
    • 73849111326 scopus 로고    scopus 로고
    • Cytochrome P450 proteins: Retention and distribution from the endoplasmic reticulum
    • Neve EPA, Ingelman-Sundberg M. Cytochrome P450 proteins: Retention and distribution from the endoplasmic reticulum. Curr. Opin. Drug Discov. Devel. 2010; 13: 78-85.
    • (2010) Curr. Opin. Drug Discov. Devel. , vol.13 , pp. 78-85
    • Neve, E.P.A.1    Ingelman-Sundberg, M.2
  • 21
    • 79251482736 scopus 로고    scopus 로고
    • Adverse reactions to zolpidem: Case reports and a review of the literature
    • PCC.09r00849. Available from, accessed 21 September 2011)
    • Inagaki T, Miyaoka T, Tsuji S, Inami Y, Nishida A, Horiguchi J. Adverse reactions to zolpidem: Case reports and a review of the literature. Prim. Care Companion J. Clin. Psychiatry. 2010; 12: PCC.09r00849. Available from:, (accessed 21 September 2011).
    • (2010) Prim. Care Companion J. Clin. Psychiatry , vol.12
    • Inagaki, T.1    Miyaoka, T.2    Tsuji, S.3    Inami, Y.4    Nishida, A.5    Horiguchi, J.6
  • 22
    • 33750293947 scopus 로고    scopus 로고
    • Visual hallucinations and amnesia associated with zolpidem triggered by fluvoxamine: A possible interaction
    • Kito S, Koga Y. Visual hallucinations and amnesia associated with zolpidem triggered by fluvoxamine: A possible interaction. Int. Psychogeriatr. 2006; 18: 749-51.
    • (2006) Int. Psychogeriatr. , vol.18 , pp. 749-751
    • Kito, S.1    Koga, Y.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.